Last reviewed · How we verify
KJ103
At a glance
| Generic name | KJ103 |
|---|---|
| Also known as | no other invention names |
| Sponsor | Shanghai Bao Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial With KJ103 in Anti-GBM Disease (PHASE2)
- A Study to Evaluate the Safety and Tolerability of KJ103 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KJ103 CI brief — competitive landscape report
- KJ103 updates RSS · CI watch RSS
- Shanghai Bao Pharmaceuticals Co., Ltd. portfolio CI